Announcement PDF I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Starpharma Holdings Limited (ASX:SPL) (US OTC:SPHRY) Renounceable Pro-rata Entitlement Offer 15 July 2026 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 The following disclaimer applies to this investor presentation and you are therefore advised to read this carefully before reading or making any other use of this presentation or any information contained in this presentation. By accepting this presentation, you represent and warrant that you are entitled to receive this presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it. This presentation has been prepared by Starpharma Holdings Limited ACN 078 532 180 (Starpharma) in connection with its underwritten renounceable pro rata entitlement offer of new fully paid ordinary shares in Starpharma (New Shares) to be made under section 708AA of the Corporations Act 2001 (Cth) (Corporations Act) (Entitlement Offer). Starpharma reserves the right to withdraw or vary the timetable for the Entitlement Offer without notice. Summary information This presentation contains summary information about Starpharma and its associated entities and their activities as at the date of this presentation (unless otherwise indicated) and the information remains subject to change without notice. The information contained in this presentation does not purport to be complete, nor include or summarise all information that an investor should consider when making an investment decision. To the maximum extent permitted by law, Starpharma is not responsible for updating, nor undertakes to update, this presentation. It should be read in conjunction with Starpharma’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. This presentation does not contain all of the information which would be required to be disclosed in a prospectus, product disclosure statement or any other offering document under Australian law or any other law (and will not be lodged with ASIC or any foreign regulator). It has been prepared by Starpharma with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this presentation by Starpharma or any other party involved in its preparation. Not a prospectus or an offer of securities This presentation is for information purposes only and is not a prospectus, product disclosure statement or other disclosure or offering document under Australian law (and will not be lodged with ASIC) or any other law. Any decision to purchase New Shares in the Entitlement Offer must be made on the basis of the information to be contained in a separate offer booklet to be prepared for shareholders (Offer Booklet) and made available following its lodgement with ASX. Any shareholder who wishes to participate in the Entitlement Offer should consider the Offer Booklet in deciding to apply under the Entitlement Offer. Anyone who wishes to apply for New Shares under the Entitlement Offer will need to apply in accordance with the instructions contained in the Offer Booklet and the application form. International offer restrictions This presentation does not constitute an offer of New Shares in any jurisdiction in which it would be unlawful. In particular, this presentation may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted in the "International Selling Restrictions" section of this presentation. By accepting this presentation you represent and warrant that you are entitled to receive the Presentation in accordance with these restrictions. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. The New Shares have not been and will not be registered under the US Securities Act of 1933, as amended (US Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be taken up, and the New Shares may not be offered or sold, directly or indirectly, to persons in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States. This presentation may not be distributed or released in the United States. 2 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Important Notice and Disclaimer I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Investment risk An investment in shares in Starpharma is subject to known and unknown risks, some of which are beyond the control of Starpharma and its directors, including possible loss of income and principal invested. Starpharma does not guarantee any particular rate of return or the performance of Starpharma, nor does it guarantee any particular tax treatment. Investors should have regard to (amongst other things) the risk factors outlined in this presentation when making their investment decision. See the “Key Risks” section of this presentation for certain risks relating to an investment in Starpharma shares. No investment or financial product advice The information contained in this presentation does not constitute investment or financial product advice (nor taxation, accounting or legal advice), is not a recommendation to acquire Starpharma shares and is not intended to be used or relied upon as the basis for making an investment decision. In providing this presentation, Starpharma has not considered the investment objectives, financial position or needs of any particular recipients. Each recipient of this presentation should make its own enquiries and investigations regarding any investment and in relation to all information in this presentation (including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Starpharma and the values and the impact that different future outcomes may have on Starpharma) and, before making any investment decisions, should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and should seek legal, accounting and taxation advice appropriate to their jurisdiction. Starpharma is not licensed to provide investment or financial product advice in respect of Starpharma shares. Future Performance This document contains certain forward looking statements and comments about future events including Starpharma’s expectations about the performance of Starpharma and forecast financial information for Starpharma. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “estimate”, “goals”, “aims”, “target” and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Forward-looking statements involve known and unknown risks, significant uncertainties, assumptions, contingencies, and other factors, many of which are outside the control of Starpharma, are subject to change without notice, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and which may cause the actual results or performance of Starpharma to be materially different from any results or performance expressed or implied by such forward-looking statements. As such, any forward looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. No representation, warranty or undertaking is made that any projection, forecast, assumption or estimate contained in this document should or will be achieved. Starpharma and the Lead Manager disclaim any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in this document to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based except as required by law. Certain information contained in this document has been obtained from published sources prepared by third parties and have not been verified by Starpharma and in certain cases has not been updated through to the date of this document. Past performance detailed in this presentation is given for illustrative purposes only and should not be relied upon as an indication of Starpharma’s views on its future financial performance or condition. Readers should note that past performance of Starpharma cannot be relied upon as an indicator of (and provides no guidance as to) future performance, including the future trading price of Starpharma’s shares, or the reasonableness of any forward looking statements, forecast financial information or other forecast. Actual results could differ materially from those referred to in the presentation. 3 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Important Notice and Disclaimer I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Financial data All dollar values are in Australian dollars ($ or AUD) unless stated otherwise. All Starpharma references starting with “FY” refer to the financial year for Starpharma, ending 30 June. For example, for Starpharma, “FY25” refers to the financial year ending 30 June 2025. This presentation contains pro forma financial information reflecting the impact of the Entitlement Offer. The pro forma financial information provided in this presentation is for illustrative purposes only and is not represented as being indicative of Starpharma's (or anyone else's) views on Starpharma's future financial position and/or performance. The pro forma financial information has been prepared by Starpharma in accordance with the measurement and recognition requirements, but not the disclosure requirements of applicable accounting standards and other mandatory requirements under the Australian Accounting Standards (AAS). Accordingly, investors should treat this information with appropriate caution. This presentation contains a number of non-IFRS financial measures under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and are not recognised under AAS or the International Financial Reporting Standards (IFRS). The non-IFRS/non-GAAP financial information has not been subject to audit or review. Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information is not a measure of financial performance, liquidity or value under the AAS or IFRS and may not be comparable to similarly titled measures presented by other entities, and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Although Starpharma believes this information provides useful information for investors and form key performance indicators for Starpharma investors are cautioned not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this presentation. Effect of Rounding A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. Disclaimer No party other than Starpharma has authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this presentation or purports to make any statement in this presentation. Canaccord Genuity (Australia) Limited (the Lead Manager) is the underwriter of the Entitlement Offer. To the maximum extent permitted by law, the Lead Manager and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (each a Limited Party): expressly exclude and disclaim any and all responsibility and liability, including, without limitation, any liability arising out of fault or negligence or in respect of any expenses, losses, damages or costs incurred by you as a result of your participation in the Entitlement Offer, from the use or reliance on information in this presentation, and the information in this presentation being inaccurate or incomplete in any way for any reason, whether by way of negligence or otherwise; and make no representations regarding, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness or fairness of that information, or that this presentation contains all information about Starpharma, the Entitlement Offer or information that a prospective investor or purchaser may require in evaluating a possible investment in Starpharma or acquisition of New Shares. 4 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Important Notice and Disclaimer I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Disclaimer (continued) The Lead Manager and its Limited Parties make no recommendation as to whether you or your related parties should participate in the Entitlement Offer nor do they make any representations or warranties to you concerning the Entitlement Offer. There is no statement in this presentation which is based on any statement by a Lead Manager or its Limited Parties. You represent, warrant, and agree that you have not relied on any statements made by a Lead Manager or other Limited Parties in relation to the Entitlement Offer and you further expressly disclaim that you are in a fiduciary relationship with any of Starpharma, the Lead Manager or its Limited Parties. You undertake that you will not seek to sue or hold the Lead Manager or its Limited Parties liable in respect in connection with this presentation or the Entitlement Offer (to the maximum extent permitted by law). The Company has appointed Canaccord Genuity (Australia) Limited (ACN 075 071 466) (Lead Manager) to act as the lead manager and underwriter to the Offer. To the maximum extent permitted by law, the Lead Manager and its related bodies corporate and affiliates, and their respective officers, directors, employees, agents and advisers (LM Parties): (i) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss (including consequential or contingent loss or damage) arising from this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this presentation; (ii) disclaim any obligations or undertaking to release any updates or revision to the information in this presentation to reflect any change in expectations or assumptions; and (iii) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this presentation or that this presentation contains all information about the Company, the Offer or that a prospective investor or purchaser may require in evaluating a possible investment in the Company or acquisition of securities in the Company, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement. The LM Parties take no responsibility for the Offer and make no recommendations as to whether any person should participate in the Offer nor do they make any representations or warranties (express or implied) concerning the Offer and they disclaim (and by accepting this presentation you disclaim) any fiduciary relationship between them and the recipients of this presentation, or any duty to the recipients of this presentation or participants in the Offer or any other person. The LM Parties have not authorised, permitted or caused the issue, submission, dispatch or provision of this presentation and, for the avoidance of doubt, and except for references to their name, none of the LM Parties makes or purports to make any statement in this presentation and there is no statement in this presentation which is based on any statement by any of them. The LM Parties may rely on information provided by or on behalf of institutional investors in connection with managing and conducting the Offer and without having independently verified that information and the LM Parties do not assume any responsibility for the accuracy or completeness of that information. The LM Parties may have interests in the securities of the Company, including by providing corporate advisory services to the Company. Further, the LM Parties may act as market maker or buy or sell those securities or associated derivatives as principal or agent. The Lead Manager will receive fees for acting in their capacity as Lead Manager to the Offer. The Lead Manager and its affiliates and related bodies corporate are full service financial institutions engaged in various activities, which may include trading, financial advisory, investment management, investment research, principal investment, hedging, market making, market lending, brokerage and other financial and non-financial activities and services including for which they have received or may receive customary fees and expenses. The Lead Manager, and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees, and agents may have interests in the securities of Starpharma, including providing investment banking services to, Starpharma. Further, they may act as market maker or buy or sell those securities or associated derivatives as principal or agent. The Lead Manager is acting as underwriter of the Entitlement Offer for which it has received or expect to receive fees and expenses. Withdrawal and cooling off Cooling off rights do not apply to the acquisition of New Shares pursuant to the Entitlement Offer. 5 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Important Notice and Disclaimer I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 6 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Summary Starpharma is today launching a fully underwritten ~A$32 million pro-rata renounceable entitlement offer (“Entitlement Offer”) • 1 for 7.5 Entitlement Offer • A$0.57 per New Share (“Offer Price”) • 25% discount to the ASX traded closing price on Tuesday 14 July 2026 Net proceeds of the Entitlement Offer will predominantly fund DEP® HER2-Lu clinical studies and new targeted DEP® oncology assets Estimated cash position post Entitlement Offer $44.5 million* extending cash runway into FY28 Focus on strategic execution and revenue generation in the next 12-18 months, including DEP® HER2-Lu program, existing partner milestones, new partner programs *Includes expected $3.5 million R&D tax incentive, refer to slide 33 for further details I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 7 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 DEP® stands for Dendrimer Enhanced Product Investment Highlights Global leader in dendrimer technology Clinically Validated DEP® Technology Platform Novel Radio- pharmaceutical Asset • DEP® HER2 in 3L HER2+ Gastric Cancer - FIH / Ph I clinical study 2H CY26 • No approved 3L therapies Three Strategic, High-value, Partnerships Positioned for Next Generation Therapies Portfolio of Partner-ready Assets • Over 20 years of dendrimer technology capabilities • Strategically managed and actively maintained patent portfolio • More than 350 patients treated with DEP® across multiple clinical programs • Two commercial consumer health products across 35+ markets Strong IP & Uniquely Experienced Team • Partnerships with Genentech, Medicxi, and Radiopharm Theranostics • Diversified source of upside with significant potential • DEP® Platform uniquely positioned to enhance efficacy and safety profile of emerging, high value, modalities— focusing on targeted oncology therapies • Phase 2 assets: DEP® SN38 and DEP® Cabazitaxel • Demonstrated efficacy and safety profile relative to SoC I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® Platform Developing Targeted Therapies Through Dendrimer Technology 8 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N J U N E 2 0 2 6 9 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Customisable DEP® technology overcomes the three reasons drugs fail in development Our DEP® Platform Solving complex challenges in drug development DEP® Solution The Challenges The Three reasons drugs FAIL in development Key Characteristics Valued by Collaborators Scalable, reproducible, site-specific attachment DEP® platform offers modifiable size, solubility, linkers and payloads Improved tumour penetration / retention, increased payload or targeting moieties per molecule Manufacturing, heterogeneous conjugation, solubility challenges Clearance, half-life, off-target tissue uptake Insufficient tumour exposure. Necessity to use high potent actives 15% Pharmacokinetics 30% Toxicity 50% Efficacy I N V E S T O R P R E S E N T A T I O N J U N E 2 0 2 6 10 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 G2 G3 G4 G5 Overview • Extensive pharmaceutical dendrimer dataset backed by 20 years of IP and know-how • Dendrimers are highly branched (tree-like) macromolecules with a well- defined 3D structure • DEP® dendrimers are constructed in concentric layers of lysine monomers called generations • DEP® dendrimers are easily scalable, precisely manufactured, and Good Manufacturing Practice (GMP) certified • Clinically validated with over 350 patients treated across multiple clinical oncology programs Our DEP® Platform Technology Global leader in dendrimer technology Dendrimer Generations Broad application across a range of treatment modalities I N V E S T O R P R E S E N T A T I O N J U N E 2 0 2 6 11 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Our DEP® Platform Technology Harnessing multiple pathways to maximise shareholder returns DEP Platform Novel asset development Strategic partnerships Multinational, private equity, biotechnology (revenue from platform license - development to commercialisation, R&D Services) Prioritising radiopharmaceuticals and other targeted oncology modalities (revenue from asset license & commercialisation) I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Evolving Asset Pipeline Strategic focus on targeted therapies and partnerships in oncology to drive shareholder value Product Target Indication Pre- clinical Phase I Phase II Phase III Status Targeted Therapies DEP® HER2 radiotherapeutic Other DEP® radio assets Targeted oncology Non-Targeted Therapies DEP® SN38 DEP® cabazitaxel Consumer Health Viraleze VivaGel® BV Commercial Commercial In Market Ovarian and colorectal Prostate and gastro-oesophageal 3L treatment resistant, HER2+, gastric cancer Various Entering Phase I Broad Spectrum Anti-Viral Bacterial Vaginosis Partner Pipeline Partner Therapeutic area Oncology Oncology Oncology (radiopharmaceuticals) Various Clinical results reported Clinical results reported Partner-ready^ Partner-ready^ In Market 12 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 ^Ongoing business development activity; supported by external advisors. I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 13 Targeting Significant Unmet Needs With First-in-class Dendrimer Technology DEP® Radiotheranostics I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® HER2-lutetium is a Targeted Radioligand Therapy Leveraging Dendrimer Technology First-in-class HER2 Radiotherapy Differentiated profile with potential to enhance tumour targeting and tolerability DEP® HER2-lutetium Optimised Design: Parameter Target Product Profile Tumour Uptake Fast tumour accumulation Tumour Retention Retention in tumour >48h Renal Clearance Fast clearance, minimal accumulation Blood Clearance Effective clearance from blood / bone marrow by 48h Efficacy HER2high and HER2low expressing tumours Indications HER2 expressing cancers (gastroesophageal, breast, etc.) HER2-targeting nanobody (VHH) Surface PEG DOTA-Lutetium-177 DEP® Dendrimer Scaffold DEP® HER2-lutetium Schematic 14 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N J U N E 2 0 2 6 15 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 T = SKOV3 (HER2+) tumour K = kidneys DEP® HER2-lutetium Achieves Strong Uptake & Retention in HER2+ Tumours Strong tumour uptake and prolonged tumour retention with low kidney exposure 2D SPECT imaging showing actual radiation signal (intensity) over time (Images not corrected for decay). SKOV3 is a HER2-high expressing cancer cell line. Mice (n=3 per group) dosed with 15 MBq of radioactivity.One representative mouse is shown per group per timepoint. • DEP® HER2-Lu vs. radiolabelled HER2-targeting VHH without dendrimer, HER2-VHH-Lu 15 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 4 hours T DEP® HER2-Lu T HER2-VHH-Lu 48 hours T T K K 5 days T T 12 days T T K DEP® HER2-Lu HER2-VHH-Lu DEP® HER2-Lu HER2-VHH-Lu DEP® HER2-Lu HER2-VHH-Lu I N V E S T O R P R E S E N T A T I O N J U N E 2 0 2 6 16 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 0 48 96 144 192 240 288 0 10 20 30 40 50 Time post-dose (hours) Radioactivity (%ID/g) Ex vivo biodistribution, SKOV3 tumour-bearing mice, n=3 per timepoint dosed with 15 MBq radioactivity; ID/g = injected dose (radioactivity) per gram of tissue; data are mean ± SEM DEP® HER2-Lu Blood Clearance Fast clearance from blood (%ID/g) Ratio in Tumour vs. Tissue 48 hours 5 days 12 days (%ID/g) 48 hours 5 days 12 days Strong tumour uptake and prolonged retention Low kidney exposure DEP® HER2-lutetium Achieves Strong Uptake & Retention in HER2+ Tumours Fast blood clearance, minimal kidney exposure and favourable tumour to tissue ratios DEP® HER2-Lu Biodistribution Tumour radioactivity ~150 times higher than blood Radioactivity in the tumour vs: 16 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 0 10 20 30 40 50 60 0 20 40 60 80 100 Time post-dose (Days) Survival (%) *** * ** 17 0 10 20 30 40 50 0 500 1000 1500 Time post-dose (Days) Tumor volume (mm 3 ) *** DEP® HER2-lutetium Achieves Significant Anti-tumour Activity and Survival Benefits Durable tumour growth control and survival benefits that are comparable to Enhertu® Mice (n=8 per group) dosed IV on Day 0. SKOV3 is a HER2-high expressing cancer cell line. Tumour volume curves displayed until volume of tumour in the first mouse in each group reaches volume endpoint (1500 mm3). Study terminated Day 57. Tumour volume data are mean ± SEM and analysed by ordinary one-way analysis of variance (ANOVA) with Dunnett’s multiple corrections on tumour growth inhibition (Day 21-Day 0) at Day 21. ***P<0.001 for DEP® HER2-Lu (15 and 25 MBq) and T-DXd (Enhertu®) vs Vehicle (phosphate buffered saline, PBS) and HER2-VHH-Lu. Survival data are analysed by Logrank (Mantel-Cox)test between two groups. *P<0.05, **P<0.01 and ***P<0.001 for each group vs. Vehicle and HER2-VHH-Lu. Anti-tumour Activity Survival Benefit DEP® HER2-Lu (25 MBq) DEP® HER2-Lu (25 MBq) 50% survival @d57 Enhertu® (10 mg/kg) 12.5% survival @d57 • HER2-positive (high-expressing) cancer model; DEP® HER2-Lu (25 MBq) and DEP® HER2-Lu (15 MBq) vs. Enhertu®, HER2-VHH-Lu and Vehicle (PBS, saline) 17 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Clinical Development Strategy Significant unmet need offers potential for Accelerated Approval FIH / Phase 1 (Imaging, dosimetry, and mass dose determination – Up to 15 patients) Phase 1/2 (Dose escalation/confirmation, expansion cohorts, efficacy, safety, up to 40 patients) Pivotal Study Phase 2/3 (Registrational, potential Fast Track – up to 250 patients) FDA Type B Pre-IND Meeting Registration H2 CY26 First patient dosed H2 CY27 Topline readout for up to 15 patients from FIH/Ph 1 Ph 1/2 (IND) begins H1 CY27 Initial data readout First 3-4 patients CY28 Phase 2/3 ready POTENTIAL FOR ACCELERATED APPROVAL 18 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Objectives • Confirm tumour targeting • Optimise mass-dose and biodistribution • Assess safety, PK and dosimetry Endpoints • PK and tumour uptake • Biodistribution / dosimetry • Safety & tolerability Next Steps • First patient H2 CY26 • Initial data H1 CY27 • Topline Phase 1 data H2 CY27 • Pre-IND/IND • Advance to Phase 1/2 expansion cohorts First-in-human Phase 1 Clinical Study I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® Radiopharmaceutical Data Supports New Patent Filing Insert speaker name and title here 19 19 I N V E S T O R P R E S E N T A T I O N J U L Y 2 0 2 6 Differentiated preclinical profile strengthens platform IP and partnering potential Differentiated Profile • Enhanced tumour uptake and retention • Low off-target and kidney exposure • Rapid blood clearance and renal excretion Broad, Modular Platform • Consistent data observed across HER2, PSMA and EGFR • Potential for an improved therapeutic window • Applicable across multiple tumour types ~US$8bn → ~US$15bn Global radiopharmaceutical market by 2030* Radiopharmaceuticals are one of the fastest-growing areas of precision oncology, attracting significant strategic interest and partnering activity from global pharmaceutical companies. IP & Par